RudaCure Inc. ha completado hoy la solicitud de patente for the eye drop formulación composition of RCI001.
This eye drop composition overcomes the physicochemical limitations of RCI001 by specifying the types and ratios of excipient components, thereby enhancing the stability of the drug.
The patent was presentó through Jin International Patent & Law Firm, which has expertise in oftálmico patents. International patents, including PCT applications, are planned to be presentó sequentially.